The deletion polymorphism of the angiotensin-converting enzyme (ACE) gene has been considered as a risk factor for IgA nephropathy and for its progression to end-stage renal failure. However, results from various studies are conflicting. We had genotyped the ACE gene in 100 patients with IgA nephropathy, 32 of whom were in end-stage renal failure and in 90 normal adult subjects. All DD cases were subjected to confirmation with a second PCR, performed with the insert-specific forward primer. Similar genotype frequencies were obtained for the 90 normal control subjects (II: 47%, ID: 44%, DD: 9%); for the 68 patients not in end-stage renal failure (ESRF) (II: 47%, ID: 46%, DD: 7%) and for the 32 patients with ESRF (II: 53%, ID: 38%, DD: 9%). The genotype frequencies in all 3 series are in Hardy-Weinberg equilibrium. These results suggest that ACE gene polymorphism is not a risk factor for IgA nephropathy and is not a predictor for its progression. Definitive proof of association between ACE gene polymorphism and progression in IgA nephropathy will require a prospective study, controlled for important risk factors, with adequate patient numbers and facility for confirming DD genotypes.

Keywords:
ACE gene polymorphism, IgA nephropathy, Disease progression
1.
Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Scubrier F: An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990;86:1343–1346.
2.
Cambien F, Poirier O, Lecerf L, Evans A, Cambou JP, Arveiler D, Luc G, Bard JM, Bara L, Ricard S, et al: Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992;359:641–644.
3.
Schunkert H, Hense JW, Holmer SR, Stender M, Perz S, Keil U, Lorell BH, Reigger GA: Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy. N Engl J Med 1994;330:1634–1638.
4.
Vleming LJ, van Kooten C, van Dijk M, Amj Hollander D, Paape ME, Westendorp RGJ, van Es LA: The D-allele of the ACE gene polymorphism predicts a stronger antiproteinuric response to ACE inhibitors. Nephrology 1998;4:143–149.
5.
Perna A, Ruggenenti P, Testa A, Spoto B, Benini R, Misefari V, Remuzzi G, Zoccali C, for the Gruppo Italiano Di Studi Epidemiologici in Nefrologia (GISEN): ACE genotype and ACE inhibitors induced renoprotection in chronic proteinuric nephropathies. Kidney Int 2000;57:274–281.
6.
Yoshida H, Mitarai T, Kawamura T, Kitajima T, Miyazaki Y, Nagasawa R, Kawaguchi Y, Kubo H, Ichikawa I, Sakai O: Role of the deletion polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy. J Clin Invest 1995;96:2162–2169.
7.
Yorioka T, Suehiro T, Yasuoka N, Hashimoto K, Kawada M: Polymorphism of the angiotensin converting enzyme gene and clinical aspects of IgA nephropathy. Clin Nephrol 1995;44:80–85.
8.
Harden PN, Geddes C, Rowe PA, McIlroy JH, Boulton-Jones M, Rodger RSC, Junor BJR, Briggs JD, Connell MC, Jardine AG: Polymorphisms in angiotensin-converting enzyme gene and progression of IgA nephropathy. Lancet 1995;345:1540–1542.
9.
Schmidt S, Stier E, Hartung R, Stein G, Bahnisch J, Woodroffe AJ, Clarkson AR, Ponticelli C, Campise M, Mayer G, Ganten D, Ritz E: No association of converting enzyme insertion/deletion polymorphism with immunoglobulin A glomerulonephritis. Am J Kidney Dis 1995;26:727–731.
10.
Hunley TE, Julian BA, Phillips JA, Summar ML, Yoshida H, Horn RG, Brown NJ, Fogo A, Ichikawa I, Kon V: Angiotensin converting enzyme gene polymorphism: Potential silencer motif and impact on progression in IgA nephropathy. Kidney Int 1996;49:571–577.
11.
Pei Y, Scholey J, Thal K, Suzuki M, Cattran D: Association of angiotensin gene T235 variant with progression of immunoglobin A nephropathy in Caucasian patients. J Clin Invest 1997;100:814–820.
12.
Suzuki S, Suzuki Y, Kobayashi Y, Harada T, Kawamura T, Yoshida H, Tomino Y: Insertion/deletion polymorphism in ACE gene is not associated with renal progression in Japanese patients with IgA nephropathy. Am J Kidney Dis 2000;35:896–903.
13.
Donadio JV, Bergstralh EJ, Offord KP, Holley KE, Spencer DC and the Mayo Nephrology Collaborative Group: Clinical and histopathologic associations with impaired renal function in IgA nephropathy. Clin Nephrol 1994;41:65–71.
14.
Hebert LA: Renoprotective therapy: How good can it get? Kidney Int 2000;57:343–344.
15.
Shanmugam V, Sell KW, Saha BK: Mistyping ACE heterozygotes. PCR Methods Appl 1993;3:120–121.
16.
Kyle CV, Abbott W, Young RP, Nijmeijer B, Simmons D, Braatvedt GD: Angiotensin-1-converting enzyme and angiotensinogen gene polymorphisms in Maori and Pacific Island people in New Zealand. Internal Med J 2001;31:116–118.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.